Genetic variants in arachidonic acid pathway genes associated with NSAID-exacerbated respiratory disease

Pharmacogenomics

Volumn 16, Issue 8, 2015, Pages 825-839

  Ayuso, Pedro ^a,b   Plaza Serón, María Del Carmen ^a,b   Blanca López, Natalia ^b   Doña, Inmaculada ^c   Campo, Paloma ^c   Canto, Gabriela ^b   Laguna, José Julio ^d   Bartra, Joan ^e   Soriano Gomis, Victor ^f   Blanca, Miguel ^c   Cornejo García, José A ^a,c   Perkins, James R ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^c UNIVERSITY OF MÁLAGA   (Spain)

^d HOSPITAL CENTRAL DE LA CRUZ ROJA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

copy number variations; hypersensitivity drug reactions; NSAID exacerbated respiratory disease; NSAIDs; polymorphisms

Indexed keywords

ACETYLSALICYLIC ACID; ADENINE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONIC ACID; CYTOSINE; DICLOFENAC; DIPYRONE; IMMUNOGLOBULIN E; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROPIONIC ACID DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROTEIN PTGS 1; PYRAZOLONE DERIVATIVE; UNCLASSIFIED DRUG; ALOX15 PROTEIN, HUMAN; CYCLOOXYGENASE 1; PTGS1 PROTEIN, HUMAN;

ADULT; ARACHIDONIC ACID METABOLISM; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; NSAID EXACERBATED RESPIRATORY DISEASE; NSAID TOLERANT ASTHMA; RHINITIS; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; AGED; DRUG HYPERSENSITIVITY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 15-LIPOXYGENASE; ARACHIDONIC ACID; ASTHMA, ASPIRIN-INDUCED; CYCLOOXYGENASE 1; DRUG HYPERSENSITIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84936988661     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.43     Document Type: Article

References (67)

1. Rubio M, Bousquet PJ, Gomes E, Romano A, Demoly P. Results of drug hypersensitivity evaluations in a large group of children and adults. Clin. Exp. Allergy 42(1), 123-130 (2012).
2. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br. J. Clin. Pharmacol. 71(5), 684-700 (2011).
3. Doña I, Blanca-Lopez N, Torres MJ et al. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J. Invest. Allergol. Clin. Immunol. 22(5), 363-371 (2012).
4. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann. Allergy Asthma Immunol. 87(3), 177-180 (2001).
5. Kowalski Ml, Asero R, Bavbek S et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 68(10), 1219-1232 (2013).
6. Doña I, Blanca-Lopez N, Cornejo-Garcia JA et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin. Exp. Allergy 41(1), 86-95 (2011).
7. Ayuso P, Blanca-Lopez N, Dona I et al. Advanced phenotyping in hypersensitivity drug reactions to NSAIDs. Clin. Exp. Allergy 43(10), 1097-1109 (2013).
8. Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol. Res. 3(1), 3-10 (2011).
9. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 328(7437), 434 (2004).
10. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur. Respir. J. 16(3), 432-436 (2000).
11. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann. Allergy Asthma Immunol. 89(5), 474-478 (2002).
12. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br. Med. J. 1(5949), 67-69 (1975).
13. Kowalski Ml, Pawliczak R, Wozniak J et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am. J. Respir. Crit. Care Med. 161(2 Pt 1), 391-398 (2000).
14. Celik G, Bavbek S, Misirligil Z, Melli M. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E(2) on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients. Clin. Exp. Allergy 31(10), 1615-1622 (2001).
15. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am. J. Respir. Cell. Mol. Biol. 23(3), 290-296 (2000).
16. Oh JM, Kim SH, Suh CH et al. Lack of association of glutathione S-transferase P1 Ile105Val polymorphism with aspirin-intolerant asthma. Korean J. Intern. Med. 20(3), 232-236 (2005).
17. Park SM, Park JS, Park HS, Park CS. Unraveling the genetic basis of aspirin hypersensitivity in asthma beyond arachidonate pathways. Allergy Asthma Immunol. Res. 5(5), 258-276 (2013).
18. Cornejo-Garcia JA, Jagemann LR, Blanca-Lopez N et al. Genetic variants of the arachidonic acid pathway in nonsteroidal anti-inflammatory drug-induced acute urticaria. Clin. Exp. Allergy 42(12), 1772-1781 (2012).
19. Fanciulli M, Petretto E, Aitman TJ. Gene copy number variation and common human disease. Clin. Genet. 77(3), 201-213 (2010).
20. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J. 31(1), 143-178 (2008).
21. Campo P, Ayuso P, Salas M et al. Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs. Allergy 68(8), 1001-1007 (2013).
22. Palikhe NS, Kim SH, Cho BY, Ye YM, Hur GY, Park HS. Association of three sets of high-affinity IgE receptor (FcepsilonR1) polymorphisms with aspirin-intolerant asthma. Respir. Med. 102(8), 1132-1139 (2008).
23. Frazer KA, Ballinger DG, Cox DR et al. A second generation human haplotype map of over 3. 1 million SNPs. Nature 449(7164), 851-861 (2007).
24. Abecasis GR, Altshuler D, Auton A et al. A map of human genome variation from population-scale sequencing. Nature 467(7319), 1061-1073 (2010).
25. Database of Single Nucleotide Polymorphisms (dbSNP). National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD, USA. (dbSNP Build ID: {build ID}). www. ncbi. nlm. nih. gov/SNP/
26. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 37, W600-W605 (2009).
27. DeFinetti program. http://ihg2. helmholtzmuenchen. de/cgi-bin/hw/hwa1. pl
28. Storey J. A direct approach to false discovery rates. J. R. Stat. Soc. B 64, 479-498 (2002).
29. Barrett JC. Haploview: visualization and analysis of SNP genotype data. Cold Spring Harb. Protoc. 2009 (10), pdb ip71 (2009).
30. Kim JH, Park Bl, Cheong HS et al. Genome-wide and followup studies identify CEP68 gene variants associated with risk of aspirin-intolerant asthma. PLoS ONE 5(11), e13818 (2010).
31. Park Bl, Kim TH, Kim JH et al. Genome-wide association study of aspirin-exacerbated respiratory disease in a Korean population. Hum. Genet. 132(3), 313-321 (2013).
32. Cornejo-Garcia JA, Flores C, Plaza-Seron MC et al. Variants of CEP68 gene are associated with acute urticaria/angioedema induced by multiple non-steroidal anti-inflammatory drugs. PLoS ONE 9(3), e90966 (2014).
33. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol. Rev. 58(3), 375-388 (2006).
34. Feltenmark S, Gautam N, Brunnstrom A et al. Eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. Proc. Natl Acad. Sci. USA 105(2), 680-685 (2008).
35. Narayanankutty A, Resendiz-Hernandez JM, Falfan-Valencia R, Teran LM. Biochemical pathogenesis of aspirin exacerbated respiratory disease (AERD). Clin. Biochem. 46(7-8), 566-578 (2013).
36. James A, Daham K, Backman L et al. The influence of aspirin on release of eoxin C4, leukotriene C4 and 15-HETE, in eosinophilic granulocytes isolated from patients with asthma. Int. Arch. Allergy Immunol. 162(2), 135-142 (2013).
37. Mastalerz L, Sanak M, Kumik J et al. Exhaled eicosanoids following bronchial aspirin challenge in asthma patients with and without aspirin hypersensitivity: the pilot study. J. Allergy (Cairo) 2012, 696792 (2012).
38. Jedrzejczak-Czechowicz M, Lewandowska-Polak A, Bienkiewicz B, Kowalski Ml. Involvement of 15-lipoxygenase and prostaglandin EP receptors in aspirin-triggered 15-hydroxyeicosatetraenoic acid generation in aspirin-sensitive asthmatics. Clin. Exp. Allergy 38(7), 1108-1116 (2008).
39. Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am. J. Pathol. 177(4), 1576-1591 (2010).
40. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem. Rev. 111(10), 5922-5943 (2011).
41. Sun YP, Oh SF, Uddin J et al. Resolvin D1 and its aspirintriggered 17R epimer. Stereochemical assignments, antiinflammatory properties, and enzymatic inactivation. J. Biol. Chem. 282(13), 9323-9334 (2007).
42. RecName: Full=Arachidonate 15-lipoxygenase; Short=15-LOX; Short=15-LOX-1; AltName: Full=12/15-lipoxygenase; AltName: Full=Arachidonate 12-lipoxygenase, leukocytetype; Short=12-LOX; AltName: Full=Arachidonate omega-6 lipoxygenase [Homo sapiens]. www. ncbi. nlm. nih. gov
43. Song YS, Yang EM, Kim SH, Jin HJ, Park HS. Effect of genetic polymorphism of ALOX15 on aspirin-exacerbated respiratory disease. Int. Arch. Allergy Immunol. 159(2), 157-161 (2012).
44. Chanock SJ, Manolio T, Boehnke M et al. Replicating genotype-phenotype associations. Nature 447(7145), 655-660 (2007).
45. Lima Jj, Zhang S, Grant A et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am. J. Respir. Crit. Care Med. 173(4), 379-385 (2006).
46. Al-Shemari H, Bosse Y, Hudson TJ et al. Influence of leukotriene gene polymorphisms on chronic rhinosinusitis. BMC Med. Genet. 9, 21 (2008).
47. Simmons Dl, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56(3), 387-437 (2004).
48. Mcadam BF, Mardini IA, Habib A et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J. Clin. Invest. 105(10), 1473-1482 (2000).
49. Pierzchalska M, Soja J, Wos M et al. Deficiency of cyclooxygenases transcripts in cultured primary bronchial epithelial cells of aspirin-sensitive asthmatics. J. Physiol. Pharmacol. 58(2), 207-218 (2007).
50. Roca-Ferrer J, Garcia-Garcia FJ, Pereda J et al. Reduced expression of COXs and production of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma. J. Allergy Clin. Immunol. 128(1), 66-72, e61 (2011).
51. Higashi N, Taniguchi M, Mita H, Osame M, Akiyama K. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Clin. Exp. Allergy 32(10), 1484-1490 (2002).
52. Helmersson J, Arnlov J, Axelsson T, Basu S. A polymorphism in the cyclooxygenase 1 gene is associated with decreased inflammatory prostaglandin F2alpha formation and lower risk of cardiovascular disease. Prostaglandins Leukot. Essent. Fatty Acids 80(1), 51-56 (2009).
53. Hahn T, Heinzel S, Plichta MM, Reif A, Lesch KP, Fallgatter AJ. Neurovascular coupling in the human visual cortex is modulated by cyclooxygenase-1 (COX-1) gene variant. Cereb. Cortex 21(7), 1659-1666 (2011).
54. Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 350(9091), 1599-1600 (1997).
55. Kawagishi Y, Mita H, Taniguchi M et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J. Allergy Clin. Immunol. 109(6), 936-942 (2002).
56. Van Sambeek R, Stevenson DD, Baldasaro M et al. 5flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirinintolerant asthma phenotype in the United States. J. Allergy Clin. Immunol. 106(1 Pt 1), 72-76 (2000).
57. Choi JH, Park HS, Oh HB et al. Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase. Hum. Genet. 114(4), 337-344 (2004).
58. Park JS, Chang HS, Park CS et al. Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet. Genomics 15(7), 483-492 (2005).
59. Jinnai N, Sakagami T, Sekigawa T et al. Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum. Mol. Genet. 13(24), 3203-3217 (2004).
60. Kim SH, Choi JH, Park HS et al. Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma. Clin. Exp. Allergy 35(5), 585-590 (2005).
61. Park BL, Park SM, Park JS et al. Association of PTGER gene family polymorphisms with aspirin intolerant asthma in Korean asthmatics. BMB Rep. 43(6), 445-449 (2010).
62. Serre D, Gurd S, Ge B et al. Differential allelic expression in the human genome: a robust approach to identify genetic and epigenetic cis-acting mechanisms regulating gene expression. PLoS Genet. 4(2), e1000006 (2008).
63. Libioulle C, Louis E, Hansoul S et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13. 1 and modulates expression of PTGER4. PLoS Genet. 3(4), e58 (2007).
64. Sakurai M, Higashide T, Takahashi M, Sugiyama K. Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost. Ophthalmology 114(6), 1039-1045 (2007).
65. Abramson SB. Clinical guidelines: expert recommendations for NSAID use: a user-friendly model? Nat. Rev. Rheumatol. 7(3), 133-134 (2011).
66. Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J. Allergy Clin. Immunol. 135(3), 676-668 (2014).
67. Perkins JR, Sanak M, Canto G, Blanca M, Cornejo-Garcia JA. Unravelling adverse reactions to NSAIDs using systems biology. Trends Pharmacol. Sci. 36(3), 172-180 (2015).